These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 10553703)
1. Toxicity of quinolones. Stahlmann R; Lode H Drugs; 1999; 58 Suppl 2():37-42. PubMed ID: 10553703 [TBL] [Abstract][Full Text] [Related]
2. Clinical toxicological aspects of fluoroquinolones. Stahlmann R Toxicol Lett; 2002 Feb; 127(1-3):269-77. PubMed ID: 12052667 [TBL] [Abstract][Full Text] [Related]
3. Fluoroquinolones in the elderly: safety considerations. Stahlmann R; Lode H Drugs Aging; 2003; 20(4):289-302. PubMed ID: 12641485 [TBL] [Abstract][Full Text] [Related]
4. Comparative tolerability of the newer fluoroquinolone antibacterials. Ball P; Mandell L; Niki Y; Tillotson G Drug Saf; 1999 Nov; 21(5):407-21. PubMed ID: 10554054 [TBL] [Abstract][Full Text] [Related]
5. Safety considerations of fluoroquinolones in the elderly: an update. Stahlmann R; Lode H Drugs Aging; 2010 Mar; 27(3):193-209. PubMed ID: 20210367 [TBL] [Abstract][Full Text] [Related]
6. [The history of the development and changes of quinolone antibacterial agents]. Takahashi H; Hayakawa I; Akimoto T Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768 [TBL] [Abstract][Full Text] [Related]
7. Children as a special population at risk--quinolones as an example for xenobiotics exhibiting skeletal toxicity. Stahlmann R Arch Toxicol; 2003 Jan; 77(1):7-11. PubMed ID: 12491034 [TBL] [Abstract][Full Text] [Related]
8. Risks associated with the therapeutic use of fluoroquinolones. Stahlmann R; Lode HM Expert Opin Drug Saf; 2013 Jul; 12(4):497-505. PubMed ID: 23651367 [TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Lipsky BA; Baker CA Clin Infect Dis; 1999 Feb; 28(2):352-64. PubMed ID: 10064255 [TBL] [Abstract][Full Text] [Related]
10. History of quinolones and their side effects. Rubinstein E Chemotherapy; 2001; 47 Suppl 3():3-8; discussion 44-8. PubMed ID: 11549783 [TBL] [Abstract][Full Text] [Related]
11. Safety of the new fluoroquinolones compared with ciprofloxacin. Ball P J Chemother; 2000 Jan; 12 Suppl 1():8-11. PubMed ID: 11414383 [TBL] [Abstract][Full Text] [Related]
12. Quinolone activity against anaerobes. Appelbaum PC Drugs; 1999; 58 Suppl 2():60-4. PubMed ID: 10553708 [TBL] [Abstract][Full Text] [Related]
14. Safety profile of the quinolones. Stahlmann R J Antimicrob Chemother; 1990 Nov; 26 Suppl D():31-44. PubMed ID: 2286589 [TBL] [Abstract][Full Text] [Related]
15. Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. De Sarro A; De Sarro G Curr Med Chem; 2001 Mar; 8(4):371-84. PubMed ID: 11172695 [TBL] [Abstract][Full Text] [Related]
17. A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats. Takizawa T; Hasimoto K; Itoh N; Yamashita S; Owen K Hum Exp Toxicol; 1999 Jan; 18(1):38-45. PubMed ID: 10025367 [TBL] [Abstract][Full Text] [Related]
18. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. Goldstein EJ Clin Infect Dis; 1996 Dec; 23 Suppl 1():S25-30. PubMed ID: 8953103 [TBL] [Abstract][Full Text] [Related]
19. Side-effects of quinolones: comparisons between quinolones and other antibiotics. Norrby SR Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):378-83. PubMed ID: 1864300 [TBL] [Abstract][Full Text] [Related]
20. A critical review of the fluoroquinolones: focus on respiratory infections. Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ Drugs; 2002; 62(1):13-59. PubMed ID: 11790155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]